P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment

Samankaltaisia teoksia

• P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
  Tekijä: Liudmila Fedorova, et al.
  Julkaistu: (2022-10-01)
• P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
  Tekijä: L. Fedorova, et al.
  Julkaistu: (2022-06-01)
• A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
  Tekijä: Kirill V. Lepik, et al.
  Julkaistu: (2020-10-01)
• A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
  Tekijä: Kirill V. Lepik, et al.
  Julkaistu: (2020-06-01)
• Long-Term Outcomes of Nivolumab Therapy in Patients with Relapsed/Refractory Classic Hodgkin’s Lymphoma after High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Real Clinical Practice
  Tekijä: Kirill Viktorovich Lepik, et al.
  Julkaistu: (2020-07-01)